Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inetetamab, Pyrotinib and Chemotherapy in First-line HER2+ Breast Cancer
NCT05621434Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of inetetamab in breast cancer, sponsored by Fujian Medical University. Primary endpoint: Progression-Free Survival up to 2 years. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
inetetamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05621434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05621434.